CD4 and neoplasm: The use of ICIs is caused by the fact that EC tumor cells are characterized by overexpression of PD-L1 and PD-L2 ligands in relation to PD-1 receptors, located on the surface of CD4+/CD8+ T lymphocytes, which infiltrate this tumor.